Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice

Transplantation

Volumn 77, Issue 9 SUPPL., 2004, Pages 1319-1326

  Koehl, Gudrun E ^a   Andrassy, Joachim ^b   Guba, M Arkus ^c   Richter, Sebastian ^a   Kroemer, Alexander ^a   Scherer, Marcus N ^a   Steinbauer, Markus ^a   Graeb, Christian ^c   Schlitt, Hans J ^a   Jauch, Karl Walter ^c   Geissler, Edward K ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; RAPAMYCIN; TRANSFORMING GROWTH FACTOR BETA;

ADVANCED CANCER; ALLOGRAFT; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER GRAFT; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; COLON ADENOCARCINOMA; CONTROLLED STUDY; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; ISOGRAFT; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; TUMOR GROWTH; VASCULAR RING;

ADENOCARCINOMA; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; COLONIC NEOPLASMS; CYCLOSPORINE; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE AGENTS; MALE; MELANOMA; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, SCID; SIROLIMUS; SKIN NEOPLASMS; TRANSPLANTATION, HOMOLOGOUS;

EID: 2442668989     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200405150-00002     Document Type: Article

References (30)

1. Garver RI, Zorn GL, Wu X, et al. Recurrence of bronchioloalveolar carcinoma in transplanted lungs. N Engl J Med 1999; 340: 1071.
2. Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation 2000; 69: 1633.
3. Fung JJ, Jain A, Kwak EJ, et al. De novo malignancies after liver transplantation: a major cause of late death. Liver Transpl 2001; 7: S109-S118.
4. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transplant 1998; 147.
5. Sheiner PA, Magliocca JF, Bodian CA, et al. Long-term medical complications in patients surviving > or = 5 years after liver transplant. Transplantation 2000; 69: 781.
6. Sheil AG. Donor-derived malignancy in organ transplant recipients. Transplant Proc 2001; 33: 1827.
7. Herman M, Weinstein T, Korzets A, et al. Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients. J Lab Clin Med 2001; 137: 14.
8. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 2001; 358: 1042.
9. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530.
10. Freise CE, Ferrell L, Liu T, et al. Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma. Transplantation 1999; 67: 510.
11. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128.
12. Luan FL, Ding R, Sharma VK, et al. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 2003; 63: 917.
13. Brattain MG, Strobel-Stevens J, Fine D, et al. Establishment of mouse colonic carcinoma cell lines with different metastatic properties. Cancer Res 1980; 40: 2142.
14. Babany G, Morris RE, Babany I, et al. Evaluation of the in vivo dose-response relationship of immunosuppressive drugs using a mouse heart transplant model: application to cyclosporine. J Pharmacol Exp Ther 1988; 244: 259.
15. Fey TA, Krause RA, Hsieh GC, et al. Improved methods for transplanting split-heart neonatal cardiac grafts into the ear pinna of mice and rats. J Pharmacol Toxicol Methods 1998; 39: 9.
16. Larsen CP, Morris PJ, Austyn JM. Migration of dendritic leukocytes from cardiac allografts into host spleens. A novel pathway for initiation of rejection. J Exp Med 1990; 171: 307.
17. Nicosia RF, McCormick JF, Bielunas J. The formation of endothelial webs and channels in plasma clot culture. Scan Electron Microsc 1984; Pt 2: 793.
18. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 623.
19. Dickson MC, Martin JS, Cousins FM, et al. Defective haematopoiesis and vasculogenesis in transforming growth factor-β 1 knock out mice. Development 1995; 121: 1845.
20. Guba M, Cernaianu G, Koehl G, et al. A primary tumor promotes dormancy of solitary tumor cells before inhibiting angiogenesis. Cancer Res 2001; 61: 5575.
21. te Velde EA, Voest EE, van Gorp JM, et al. Adverse effects of the antiangiogenic agent angiostatin on the healing of experimental colonic anastomoses. Ann Surg Oncol 2002; 9: 303.
22. Kings-Biggs MB, Dunitz JM, Parks SJ, et al. Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation 2003; 75: 1437.
23. S6K pathway in human pancreatic cancer cells. Cancer Res 1999; 59: 3581.
24. Seeliger H, Guba M, Koehl G, et al. Blockage of 2-deoxy-D-Ribose induced angiogenesis with Rapamycin counteracts a thymidine phosphorylase-based excape mechanism available for colon cancer under 5-fluorouracil therapy. Clin Cancer Res 2004; 10: 1843.
25. Guba M, Graeb C, Jauch KW, et al. Pro and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 2004; in press.
26. Luan FL, Hojo M, Maluccio M, et al. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002; 73: 1565.
27. Thomson AW, Lu L. Are dendritic cells the key to liver transplant tolerance? Immunol Today 1999; 20: 27.
28. Garcia-Hernandez ML, Hernandez-Pando R, Gariglio P, et al. Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation. Immunology 2002; 105: 231.
29. Lee WC, Qiani S, Wan Y, et al. Contrasting effects of myeloid dendritic cells transduced with an adenoviral vector encoding interleukin-10 on organ allograft and tumour rejection. Immunology 2000; 101: 233.
30. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096.